Friday, June 13, 2025
6/13/2025
RSK3 Anchoring Disruptor Therapy for Heart Failure - Novel therapeutic approaches are desperately needed in an expanding patient population to improve both the survival and quality of life for patients with or susceptible to heart failure. Research over the last two decades has established p90 ribosomal S6 kinase type 3 (RSK3) as a pivotal regulator of pathological cardiac remodeling, including in mouse models of pressure overload and genetic cardiomyopathy. RSK3 is required for pathological remodeling even though RSK3 is less abundant in the cardiac myocyte than other members of the RSK protein kinase family. The efficiency and specificity of intracellular signal transduction can be enhanced by the anchoring and co-localization of key enzymes and their upstream activators and substrate effectors by scaffold proteins. RSK3’s unique N-terminal domain confers high affinity binding to the scaffold protein muscle A-kinase anchoring protein β (mAKAPβ) in the cardiac myocyte. Recently published data show that blockade of RSK3 association with mAKAPβ by adeno-associated virus (AAV) mediated expression of the mAKAPβ-derived RSK3 Binding Domain (RBD) anchoring disruptor polypeptide will inhibit the development of pathological remodeling and heart failure during chronic pressure overload in the mouse. Newer data demonstrate that RBD expression will also prevent remodeling following myocardial infarction (MI) in the mouse. Cardiac RSK3 Inhibitors, LLC (CRI Biotech) is a company developing patent-protected therapeutics targeting cardiac myocyte mAKAPβ signalosomes for the prevention and/or treatment of heart failure. To target mAKAPβ-RSK3-dependent signaling via blockade of the mAKAPβ-RSK3 protein-protein interaction, CRI Biotech proposes to treat patients at risk for heart failure with the new self-complementary, serotype 9 AAV gene therapy vector AAV9sc.RBD. As a dose sufficient to deliver AAV9sc.RBD with high penetrance to the swine myocardium has been determined, CRI Biotech will now test in this Direct to Phase II SBIR project the efficacy of AAV9sc.RBD in a clinically relevant swine model of ischemic cardiomyopathy. Specific Aim 1: Efficacy of RSK3 anchoring disruptor peptide for post-myocardial infarction heart failure in a large animal model. The core of this project is to test whether RBD peptide expression will reduce pathological remodeling induced by MI in swine, preventing heart failure. Swine will be subjected to ischemia-reperfusion injury to induce MI and then treated immediately afterwards with AAV9sc.RBD by antegrade intracoronary infusion. Cardiac function will be assessed serially for 12 weeks post- MI. Specific Aim 2: AAV9sc.RBD-mediated inhibition of the molecular and cellular pathology associated with heart failure. Taking advantage of tissue collected from the same animals used in Specific Aim 1, the benefits of the RBD anchoring disruptor biologic in swine will be further demonstrated by gravimetric, histological, and molecular analyses for fibrosis and other markers of cardiac remodeling and heart failure. In addition, initial toxicology screens will be done to test AAV9sc.RBD safety.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).